Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Gains from Investment Securities: 2009-2025

Historic Gains from Investment Securities for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to $300,000.

  • Myriad Genetics' Gains from Investment Securities fell 90.00% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 24.82%. This contributed to the annual value of $13.4 million for FY2024, which is 52.27% up from last year.
  • As of Q3 2025, Myriad Genetics' Gains from Investment Securities stood at $300,000, which was down 94.83% from $5.8 million recorded in Q1 2025.
  • Over the past 5 years, Myriad Genetics' Gains from Investment Securities peaked at $8.7 million during Q1 2024, and registered a low of $200,000 during Q2 2022.
  • Over the past 3 years, Myriad Genetics' median Gains from Investment Securities value was $1.9 million (recorded in 2023), while the average stood at $2.8 million.
  • Per our database at Business Quant, Myriad Genetics' Gains from Investment Securities surged by 325.00% in 2022 and then crashed by 90.00% in 2025.
  • Myriad Genetics' Gains from Investment Securities (Quarterly) stood at $2.9 million in 2021, then tumbled by 48.28% to $1.5 million in 2022, then remained steady at $1.5 million in 2023, then declined by 20.00% to $1.2 million in 2024, then slumped by 90.00% to $300,000 in 2025.
  • Its last three reported values are $300,000 in Q3 2025, $5.8 million for Q1 2025, and $1.2 million during Q4 2024.